title: Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.
abstract: Hematopoietic stem cell transplantation (HSCT) is a curative treatment for otherwise incurable diseases. Conditioning regimen is an important part of HSCT and consists of chemotherapy with or without irradiation. Conditioning exerts myelosuppressive, immunosuppressive and antitumor effects, but also contributes to HSCT-related complications including graft-versus-host disease (GVHD). Since almost 50% of the transplanted patients are conditioned with cytostatics without irradiation, we developed and characterized a GVHD mouse model following conditioning with busulphan and cyclophosphamide. Recipient Balb/c female mice were treated with busulphan (20 mg/kg/day for 4 days) and cyclophosphamide (100 mg/kg/day for two days). After one day of rest, recipient mice were transplanted with 2×10(7) bone marrow and 3×10(7) spleen cells from male C57BL/6 (allogeneic group) or female Balb/c (syngeneic/control group) mice. The allogeneic, but not syngeneic transplanted mice developed GVHD. Histopathology of the major internal organs (liver, pancreas, spleen, lungs, heart and kidney) was examined before conditioning start, after conditioning's end and 5, 7 and 21 days after transplantation using hematoxylin-eosin staining. Decreased spleen cellularity and diminished glycogen content in the liver were observed after conditioning regimen. Histopathological changes such as vasculitis, inflammation and apoptotic cell forms in liver, spleen, pancreas, lungs and heart were observed in allogeneic transplanted mice, however, only hypocellular spleen and extramedullar hematopoiesis were detected in syngeneic transplanted animals. No morphological changes were observed in kidney in either HSCT setting. This is the first study describing early histopathological changes after conditioning regimen with busulphan/cyclophosphamide and dynamics of GVHD development in several major internal organs.
authors: Experimental Cancer Medicine, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
authors: Sulaiman
authors: S
authors: Al-Hashmi
authors: Zuzana
authors: Z
authors: Hassan
authors: Behnam
authors: B
authors: Sadeghi
authors: Björn
authors: B
authors: Rozell
authors: Moustapha
authors: M
authors: Hassan
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000494:pharmacology*; D017690:Cell Transplantation; D003520:Cyclophosphamide / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000473:pathology*; D006411:Hematopoiesis, Extramedullary / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008112:Liver Glycogen / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019653:Myeloablative Agonists / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects / Q000473:pathology; D013154:Spleen / Q000166:cytology; D019172:Transplantation Conditioning / Q000379:methods*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D008112:Liver Glycogen; D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D002066:Busulfan